Viatris Inc. is a global pharmaceutical company operating in the healthcare sector, focused on the development, manufacturing, and distribution of medicines across a wide range of therapeutic areas. The company was formed through the combination of Mylan N.V. and Upjohn, a division of Pfizer.

Its business model is centered on expanding access to medicines through a diversified portfolio that includes both established and complex therapies.

Core activities include:

• Production of generic and branded medicines

• Development and commercialization of biosimilars

• Manufacturing of specialty and chronic-care treatments

• Global pharmaceutical distribution and supply chain management

• Research and development across multiple therapeutic categories

Viatris operates in more than 150 countries, with a strong presence in North America, Europe, Asia-Pacific, and Latin America, serving hospitals, pharmacies, distributors, and public health systems.

The company’s performance is influenced by regulatory frameworks, patent cycles, pricing pressures, demand for affordable medicines, growth in biosimilars, and demographic trends such as global population aging.

Viatris Inc. is listed on the Nasdaq under the ticker VTRS.

History and Development

Viatris was established in 2020 in the United States following the merger between Mylan N.V. and Upjohn, Pfizer’s division focused on established medicines.

Its initial phase was marked by the integration of global operations, consolidation of manufacturing and supply chains, and reorganization of its product portfolio to align with strategic priorities. Following its formation, the company expanded its presence in international markets, strengthened its position in biosimilars and specialty treatments, and optimized production and commercial strategies to improve competitiveness.

The post-merger period also included portfolio adjustments, divestment of non-core assets, and initiatives aimed at reducing debt and improving operational efficiency. Today, Viatris continues to operate as a global pharmaceutical provider, focusing on accessibility, portfolio diversification, and the expansion of its presence across developed and emerging markets.

Additional Information

Viatris Inc. (United States) is listed on the Nasdaq and has a market capitalization of $20.11 billion, with shareholders equity totaling $14.66 billion.

The company employs approximately 45.000 people and operates in the Health sector, within the Pharmaceutical Products industry.

Over the past 12 months, Viatris Inc. reported $14.56 billion in revenue, generating net income of $-296.50 million.

Key financial metrics include a P/E ratio of -67.82, a price-to-book (P/B) ratio of 1.37, and a trailing twelve-month dividend yield of 2.76%.

The company trades under the ticker VTRS.